A observational study on the influencing factors of quality of life scale in ulcerative colitis
-
摘要: 目的 探讨影响溃疡性结肠炎患者生存质量的相关因素，以期为改善患者的生存质量提供指导。方法 选取2019年8月—2022年1月就诊于南京中医药大学附属医院、北京中医药大学东方医院、中国中医科学院望京医院的354例UC患者的调查信息，构建数据库，基于SPSS 26.0进行频数、线性回归方程等统计分析。观察不同因素对患者健康调查简表(SF-36量表)得分的影响。结果 BMI影响生理功能(P=0.003)、躯体职能(P=0.015)、总体健康(P=0.024)、精力(P=0.001)和精神健康(P=0.033)维度得分；性别因素影响躯体疼痛(P=0.007)、总体健康(P=0.024)和精神健康(P=0.005)维度得分；Mayo积分影响生理功能(P=0.002)、躯体职能(P=0.005)、躯体疼痛(P=0.029)和总体健康(P=0.013)维度得分；肠外表现影响生理功能(P=0.015)和躯体疼痛(P < 0.001)维度得分；病变范围影响躯体疼痛(P=0.047)维度得分；临床分期影响精神健康(P=0.015)维度得分。BMI、病变范围、Mayo积分影响总分的高低。结论 性别、BMI、Mayo积分、疾病分期、病变部位等因素对溃疡性结肠炎患者的生存质量量表得分有影响。Abstract: Objective Investigate the related factors of quality of life in patients with ulcerative colitis, and provide guidance for improving the quality of life of patients.Methods A total of 354 patients with ulcerative colitis who were admitted to the Affiliated Hospital of Nanjing University of Chinese Medicine, Dongfang Hospital of Beijing University of Chinese Medicine and Wangjing Hospital of China Academy of Chinese Medical Sciences from August 2019 to January 2022 were selected to construct the database. Statistical analysis of frequency and linear regression equation was conducted based on SPSS 26.0.Results Observe the effects of different factors on the score of the SF-36 scale, and the results showed that BMI affected the scores of PF(P=0.003), RP(P=0.015), GH(P=0.024), VT(P=0.001) and MH(P=0.033). Gender factors affected the scores of BP(P=0.007), GH(P=0.024) and MH(P=0.005). Mayo index affects the scores of PF(P=0.002), RP(P=0.005), BP(P=0.029), and GH(P=0.013). Extraintestinal manifestations affected the scores of PF(P=0.015) and BP(P < 0.001). The range of lesions affected the score of BP(P=0.047). Clinical stage affected mental health score(P=0.015). BMI, lesion range and Mayo index affected the total score.Conclusion Factors such as gender, BMI, Mayo score, disease stage and lesion range had influence on QOL scale score of patients with ulcerative colitis.
-
Key words:
- ulcerative colitis /
- quality of life /
- survey health profile /
- SF-36 scale /
- influence factor
-
-
表 1 不同因素变量及赋值
因素 变量 赋值 1 2 3 4 性别 X1 男 女 年龄/岁 X2 < 60 ≥60 病程/年 X3 < 5 5~ < 10 ≥10 吸烟史 X3 是 否 BMI X4 < 18.5 18.5~ < 24.0 ≥24.0 临床类型 X5 初发型 慢性复发型 临床分期 X6 活动期 缓解期 病变范围 X7 直肠 左半结肠 广泛结肠 肠外表现 X8 有 无 Mayo积分/分 X9 ≤2 3~5 6~10 11~12 服用中药 X10 是 否 服用激素 X11 是 否 
下载: 导出CSV
表 2 不同维度与影响因素回归模型评估
PF RP BP GH VT MH 德宾-沃森指数 2.078 2.097 1.952 2.030 2.166 2.109 R值 0.335 0.297 0.332 0.345 0.264 0.276 R2值 0.112 0.088 0.110 0.119 0.070 0.076 P < 0.001 0.001 < 0.001 < 0.001 0.015 0.007
下载: 导出CSV
表 3 不同因素在量表不同维度的得分特征及线性回归分析
M(P25，P75) 维度 因素 赋值/分 Bate P 1 2 3 4 BMI 85(78，94) 93(90，99) 95(95，99) 0.161 0.003 PF 肠外表现 80(68，89) 95(90，95) 0.127 0.015 Mayo积分 98(90，100) 95(90，95) 90(81，95) 85(61，85) -0.207 0.002 RP BMI 25(0，69) 50(31，88) 38(6，94) 0.134 0.015 Mayo积分 75(6，100) 38(38，50) 75(25，75) 25(0，88) -0.187 0.005 性别 79(60，89) 68(25，82) -0.158 0.007 BP 病变范围 74(63，89) 84(74，90) 68(25，84) -0.105 0.047 肠外表现 52(31，74) 79(55，89) 0.191 0.000 Mayo积分 84(84，88) 74(25，89) 74(62，86) 62(36，82) -0.143 0.029 性别 45(34，49) 54(26，59) -0.130 0.024 GH BMI 45(29，59) 46(29，56) 48(31，52) 0.194 0.000 Mayo积分 50(41，75) 43(27，52) 45(40，49) 28(25，48) -0.163 0.013 VT BMI 60(55，70) 70(58，79) 75(61，79) 0.183 0.001 性别 58(53，68) 48(33，60) -0.166 0.005 MH BMI 58(42，63) 54(40，59) 56(41，68) 0.119 0.033 临床分期 60(52，68) 58(41，60) -0.162 0.015
下载: 导出CSV
表 4 不同影响因素与量表总分的相关性
影响因素 R值 P 性别 -0.134 0.011 年龄 -0.011 0.840 病程 0.046 0.393 吸烟史 -0.029 0.586 BMI 0.181 0.001 临床类型 0.037 0.493 临床分期 0.079 0.136 病变范围 -0.140 0.008 肠外表现 0.101 0.057 Mayo积分总分 -0.177 0.001 服用中药 0.034 0.528 服用激素 -0.004 0.943
下载: 导出CSV
表 5 不同因素对量表总得分影响的特征及线性回归结果
M(P25，P75) 维度 赋值/分 Bate P 1 2 3 4 BMI 61(43，79) 70(10，80) 58(49，83) 2.961 0.003 病变范围 70(45，78) 70(58，79) 60(45，81) -2.049 0.041 Mayo积分 71(58，88) 63(58，74) 71(52，84) 49(40，71) -2.713 0.007
下载: 导出CSV
-
[1] Kato S, Ishibashi A, Kani K, et al. Optimized management of ulcerative proctitis: when and how to use mesalazine suppository[J]. Digestion, 2018, 97(1): 59-63. doi: 10.1159/000484224
[2] Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778. doi: 10.1016/S0140-6736(17)32448-0
[3] The World Health Organization Quality of Life Assessment (WHOQOL). Development and general psychometric properties[J]. Soc Sci Med, 1998, 46(12): 1569-1585. doi: 10.1016/S0277-9536(98)00009-4
[4] 张声生, 沈洪, 郑凯, 等. 溃疡性结肠炎中医诊疗专家共识意见(2017)[J]. 中华中医药杂志, 2017, 32(8): 3585-3589. https://www.cnki.com.cn/Article/CJFDTOTAL-BXYY201708071.htm
[5] Plevris N, Lees CW. Disease monitoring in inflammatory bowel disease: evolving principles and possibilities[J]. Gastroenterology, 2022, 162(5): 1456-1475. e1. doi: 10.1053/j.gastro.2022.01.024
[6] Ho PYM, Hu WJ, Lee YY, et al. Health-related quality of life of patients with inflammatory bowel disease in Singapore[J]. Intest Res, 2019, 17(1): 107-118. doi: 10.5217/ir.2018.00099
[7] Gao ZY, Wang P, Hong J, et al. Health-related quality of life among Chinese patients with Crohn's disease: a cross-sectional survey using the EQ-5D-5 L[J]. Health Qual Life Outcomes, 2022, 20(1): 62. doi: 10.1186/s12955-022-01969-z
[8] 吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018, 38(9): 796-813. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201809007.htm
[9] 万崇华, 方积乾, 史明丽, 等. MOS SF-36量表用于药物成瘾者生命质量测定的对比研究[J]. 中国行为医学科学, 1998, 7(4): 260-261, 259. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXX199804008.htm
[10] Yamamoto-Furusho JK, Gutiérrez-Grobe Y, López-Gómez JG, et al. The Mexican consensus on the diagnosis and treatment of ulcerative colitis[J]. Rev Gastroenterol Mex (Engl Ed), 2018, 83(2): 144-167.
[11] Rijcken E, Senninger N, Mennigen R. Restorative proctocolectomy for ulcerative colitis: long-term functional results and quality of life[J]. Chirurg, 2017, 88(7): 566-573. doi: 10.1007/s00104-017-0441-0
[12] Panés J, Vermeire S, Lindsay JO, et al. Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies[J]. J Crohns Colitis, 2019, 13(1): 139-140. doi: 10.1093/ecco-jcc/jjy135
[13] 黄丹, 陈芳, 胡韬韬. 老年CKD患者生存质量及影响因素[J]. 中国老年学杂志, 2022, 42(7): 1744-1747. doi: 10.3969/j.issn.1005-9202.2022.07.060
[14] 刘宸希, 殷文静, 王砚丽. 不同年龄段结直肠癌患者生存质量及其影响因素[J]. 中国卫生工程学, 2021, 20(5): 781-782. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202105028.htm
[15] 吕民, 李苓. 甲状腺癌患者生存质量调查及影响因素[J]. 中国卫生工程学, 2021, 20(4): 611-612. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWX202104027.htm
[16] Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders[J]. J Crohns Colitis, 2017, 11(6): 649-670.
[17] Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J]. J Crohns Colitis, 2016, 10(3): 239-254.
[18] Portela F, Ministro P, de Deus J, et al. Health-related quality of life in patients with moderate to severe ulcerative colitis: surgical intervention versus immunomodulatory therapy[J]. Digestion, 2020, 101(5): 631-637.
-